
[9] Pathogenic elevations of bile acid levels have been linked to variations in FGF19 levels (Vergnes et al., Cell Metabolism (2013) 17, 916-28). Reduction in the level of FGF19 may therefore be of benefit in promoting the synthesis of bile acid and thus in the treatment of hyperlipidemia.

[10] There is still a need for new FGFR4 inhibitors. In this regard, the compounds provided herein address the need.

BRIEF SUMMARY

[10a] In an aspect of the present disclosure, there is provided a compound of formula (I):



(I),

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

---- is a single bond or a double bond;

X is CH or C;

L_1 is -CR'R"-, -O-, or -NR'"-, wherein R' and R" are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, or halo, and R'" is H, C_{1-6} alkyl, C_{1-6} haloalkyl, or acyl;

L_2 is a bond or -CH_2-;

A is a C_{6-14} arylene, 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene,

provided that when L_1 is -CH_2- and L_2 is a bond, then A is 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene;

R^1, R^2, R^3, R^4, and R^5 are each independently H, halo, -OCD_3, -CN, -NO_2, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, -OR^{13}, or -$NR^{11}R^{12}$,

or R^1 and X are taken together with the carbons to which they are attached to form a 4- to 8- membered heterocyclyl;

m is 0, 1, or 2;

each R^7 is independently halo, -CN, -NO_2, C_{1-6} alkyl, -CD_3, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, -OR^{13}, or -NR^aR^b, wherein R^a and R^b are each independently H or C_{1-6} alkyl optionally substituted by -NR^cR^d, wherein R^c and R^d are each independently H or C_{1-6} alkyl;

R^8 is –$C(O)R^9$ or –$S(O)_2R^9$;

R^9 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl, each of which is optionally substituted with C_{1-6} alkyl, halo, -CN, or –$C(O)OR^{9a}$, wherein R^{9a} is C_{1-6} alkyl; and

R^{11}, R^{12}, and R^{13} are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} heteroalkyl, C_{6-14} aryl, 5- to 10- membered heteroaryl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl;

provided that the compound is not a compound selected from the group consisting of:

N-(3-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-pyrazol-4-yl)acrylamide,

N-(3-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2,6-difluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2-fluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,


N-(5-(6-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide, and

N-(5-(6-(2-chloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

[10b] In another aspect of the present disclosure, there is provided a compound of formula (II):



(II),

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

L_1 is -CR'R''-, -O-, or -NR'''-, wherein R' and R'' are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, or halo, and R''' is H, C_{1-6} alkyl, C_{1-6} haloalkyl, or acyl;

A is a C_{6-14} arylene, 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene;R^1, R^2, R^3, R^4, and R^5 are each independently H, halo, $-OCD_3$, -CN, $-NO_2$, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, $-OR^{13}$, or $-NR^{11}R^{12}$,

or R^1 and X are taken together with the carbons to which they are attached to form a 4- to 8- membered heterocyclyl;

m is 0, 1, or 2;



each R^7 is independently halo, -CN, $-NO_2$, C_{1-6} alkyl, $-CD_3$, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, $-OR^{13}$, or $-NR^aR^b$, wherein R^a and R^b are each independently H or C_{1-6} alkyl, wherein the C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, and $-OR^{13}$ of R^7 and the C_{1-6} alkyl of R^a and R^b are each independently optionally substituted by $-NR^cR^d$, wherein R^c and R^d are each independently H or C_{1-6} alkyl;

R^8 is $–C(O)R^9$ or $–S(O)_2R^9$;


R^9 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl, each of which is optionally substituted with C_{1-6} alkyl, halo, -CN, or $–C(O)OR^{9a}$, wherein R^{9a} is C_{1-6} alkyl; and


R^{11}, R^{12}, and R^{13} are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} heteroalkyl, C_{6-14} aryl, 5- to 10- membered heteroaryl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl.



[10c] In a further aspect of the present disclosure, there is provided a compound selected from the group consisting of



;


;




;

;



;

;


trans


;




;




;




;




;











;





















;





;



;

;

;

;

;

;

;

;


;

;

;

;

;

;

;

;


;

;

;

;

;

;

;

;

;

;



;


; and


,

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

[10d] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising at least one compound disclosed herein, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier or excipient.


[10e] In a further aspect of the present disclosure, there is provided a kit comprising at least one compound disclosed herein, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing.

[10f] In another aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing in the manufacture of a medicament for treating a disease mediated by FGFR4.

[10g] In a further aspect of the present disclosure, there is provided a use of a compound disclosed herein, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing in the manufacture of a medicament for inhibiting FGFR4.

[10h] In another aspect of the present disclosure, there is provided a compound disclosed herein, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing, for use in therapy.

[11] In one example, provided herein is a compound of formula (I):



(I),

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein ----, X, L_1, L_2, A, m, R^1, R^2, R^3, R^4, R^5, R^7, and R^8 are as described herein.


[12] In another example, provided herein is a composition comprising a compound of formula (I) or any related formula, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing and a pharmaceutically acceptable carrier or excipient.

[13] In another example, provided herein is a kit comprising a compound of formula (I) or any related formula, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing.

[14] In another example, provided herein is a method of treating a disease mediated by FGFR4 in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of formula (I) or any related formula, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing. In some examples, the compound, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing, is administered orally. In some examples, the disease is cancer. In some examples, the disease is liver cancer such as hepatocellular carcinoma,

CLAIMS

1. A compound of formula (I):



(I),

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

---- is a single bond or a double bond;

X is CH or C;

L_1 is -CR'R"-, -O-, or -NR'"-, wherein R' and R" are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, or halo, and R'" is H, C_{1-6} alkyl, C_{1-6} haloalkyl, or acyl;

L_2 is a bond or $-CH_2-$;

A is a C_{6-14} arylene, 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene,

provided that when L_1 is $-CH_2-$ and L_2 is a bond, then A is 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene;

R^1, R^2, R^3, R^4, and R^5 are each independently H, halo, $-OCD_3$, -CN, $-NO_2$, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, $-OR^{13}$, or $-NR^{11}R^{12}$,

or R^1 and X are taken together with the carbons to which they are attached to form a 4- to 8- membered heterocyclyl;

m is 0, 1, or 2;

each R^7 is independently halo, -CN, $-NO_2$, C_{1-6} alkyl, $-CD_3$, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, $-OR^{13}$, or $-NR^aR^b$, wherein R^a and R^b are each independently H or C_{1-6} alkyl optionally substituted by $-NR^cR^d$, wherein R^c and R^d are each independently H or C_{1-6} alkyl;

R^8 is $–C(O)R^9$ or $–S(O)_2R^9$;

R^9 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl, each of which is optionally substituted with C_{1-6} alkyl, halo, -CN, or $–C(O)OR^{9a}$, wherein R^{9a} is C_{1-6} alkyl; and

R^{11}, R^{12}, and R^{13} are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} heteroalkyl, C_{6-14} aryl, 5- to 10- membered heteroaryl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl;

provided that the compound is not a compound selected from the group consisting of:

N-(3-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-pyrazol-4-yl)acrylamide,

N-(3-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2,6-difluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2-fluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,


N-(5-(6-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide, and

N-(5-(6-(2-chloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

2. A compound of formula (II):



(II),

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

L_1 is -CR'R"-, -O-, or -NR"'-, wherein R' and R" are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, or halo, and R"' is H, C_{1-6} alkyl, C_{1-6} haloalkyl, or acyl;

A is a C_{6-14} arylene, 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene;R^1, R^2, R^3, R^4, and R^5 are each independently H, halo, -OCD_3, -CN, -NO_2, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, -OR^{13}, or -$NR^{11}R^{12}$,

or R^1 and X are taken together with the carbons to which they are attached to form a 4- to 8- membered heterocyclyl;

m is 0, 1, or 2;


each R^7 is independently halo, -CN, -NO_2, C_{1-6} alkyl, -CD_3, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, -OR^{13}, or -NR^aR^b, wherein R^a and R^b are each independently H or C_{1-6} alkyl, wherein the C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, and -OR^{13} of R^7 and the C_{1-6} alkyl of R^a and R^b are each independently optionally substituted by -NR^cR^d, wherein R^c and R^d are each independently H or C_{1-6} alkyl;

R^8 is –$C(O)R^9$ or –$S(O)_2R^9$;

R^9 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl, each of which is optionally substituted with C_{1-6} alkyl, halo, -CN, or –$C(O)OR^{9a}$, wherein R^{9a} is C_{1-6} alkyl; and


R^{11}, R^{12}, and R^{13} are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} heteroalkyl, C_{6-14} aryl, 5- to 10- membered heteroaryl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl.

3. The compound of claim 1 or 2, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (II-a):




(II-a).

4. The compound of claim 1, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (III):




(III).

5. The compound of claim 1 or 4, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (III-a):




(III-a).

6. The compound of claim 1 or 4, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (III-b):



(III-b).

7. The compound of claim 1 or 4, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (III-c):



(III-c).

8. The compound of claim 1 or 4, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein

(a) ---- is a single bond; or

(b) ---- is a double bond; or

(c) L_1 is -CR'R''-; or

(d) L_1 is -O- or -NR'''-; or

(e) L_2 is a bond; or

(f) L_2 is -CH_2-.

9. The compound of any one of claims 1-6 and 8, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein

(a) R' is H; or

(b) R' is C_{1-6} alkyl, and optionally methyl; or

(c) (i) R'' is H, or

(ii) R'' is C_{1-6} alkyl, C_{1-6} haloalkyl, or halo.

10. The compound of any one of claims 1-9, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein

(a) R^2 is $-OR^{13}$ and R^{13} is C_{1-6} alkyl, and optionally R^2 is $-OCH_3$ or $-OCD_3$; and/or

(b) R^3 is H; and/or

(c) R^4 is $-OR^{13}$ and R^{13} is C_{1-6} alkyl, and optionally R^4 is $-OCH_3$ or $-OCD_3$; and/or






(d) (i) R^5 is H, or

(ii) R^5 is halo; and/or

(e) (i) R^1 is H, or

(ii) R^1 is halo.

11. The compound of any one of claims 1 or 8-9, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 and X are taken together with the carbons to which they are attached to form a 4- to 8- membered heterocyclyl.

12. The compound of any one of claims 1-11, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is a C_6 arylene, 5- to 6-membered heteroarylene, C_{5-6} cycloalkylene, or 5- to 6- membered heterocyclylene, and optionally A is , , , , or .

13. The compound of any one of claims 1-12, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein

(a) m is 0; or




(b) m is 1.

14. The compound of any one of claims 1-13, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein each R^7 is independently C_{1-6} alkyl or C_{1-6} haloalkyl, and optionally each R^7 is independently $-CH_3$, $-CH_2CH_3$, $-CH(CH_3)_2$, $-CD_3$, or $–CH_2CF_3$.



15. The compound of any one of claims 1-14, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein



(a) R^8 is $–C(O)R^9$; or



(b) R^8 is $–S(O)_2R^9$.


16. The compound of any one of claims 1-15, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^9 is C_{1-6} alkyl, C_{2-6} alkenyl, or 3- to 10- membered heterocyclyl, each of which is optionally substituted with halo or $–C(O)OR^{9a}$, wherein R^{9a} is C_{1-6} alkyl, and optionally R^9 is $-CH_3$, $-CH_2CH_3$, , , , or .

17. A compound selected from the group consisting of


; ;

; ;


; ;


trans


;




;




;




;




;











;





















;





;



;

;

;

;

;

;

;

;


O
HN
HN
N
F
O
N
NH
O
;

O
HN
HN
N
F
O
N
N
O
;

O
O
F
H
N
O
N
H
N
N
N
O
;

O
F
O
F
H
N
N
HN
O
O
;

O
F
O
H
N
N
HN
O
O
;

O
F
O
F
H
N
N
HN
O
O
;

O
F
O
H
N
N
HN
O
O
;

O
F
O
F
H
N
N
N
HN
N
O
;


;

;

;

;

;

;

;

;

;

;



;


; and


,

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

18. A pharmaceutical composition comprising at least one compound according to any one of claims 1-17, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier or excipient.

19. A kit comprising at least one compound according to any one of claims 1-17, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing.

20. Use of a compound according to any one of claims 1-17, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing in the manufacture of a medicament for treating a disease mediated by FGFR4.

21. The use of claim 20, wherein the compound is to be administered orally.

22. The use of claim 20, wherein the disease is cancer.

23. Use of a compound according to any one of claims 1-17, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing in the manufacture of a medicament for inhibiting FGFR4.

24. A compound of any one of claims 1-17, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing, for use in therapy.